The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
earth70000
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine
They used 43000 not 170.
I'm not exactly surprised that people believe this stuff.
There is a danger here of sounding like a certain US President when presented with facts that he lost the election.
There are 2 things here, 1) efficacy of the vaccine and 2) safety of the vaccine.
If you're going to complain about the safety of the vaccine and ask questions about liability then you really can't use the stat of 162 vs 8 people, feel free to argue about efficacy though.
If you want to talk about safety, you need to use the 44,000 number and that the major side effects where i) fatigue and ii) headache.
Testing will still be needed for a while yet, doesn't mean that any other branch of medical science needs to be trashed.
The likely number is probably alot higher, certainly in the Western world it's probably about 0.1%, so 1 in 1000, people.
eg in the UK we are at 55k officially, but deaths above average is a bit higher, call it 65k vs population of 68m.
That's with all the madness, with the hospitals just about staying the right side of the red line, it could quite easily be alot worse if we'd not had all the "Madness".
How much worse? 5 times worse if we'd not locked down and the NHS cracked under pressure maybe. That would be 1 in 200.
All of a sudden everyone knows at least one person who's passed.
Go to an average secondary school and 30 kids (a whole class) will have had a parent or grandparent die.
Because they are a huge multinational pharma and a vaccine will make them money but not huge amounts. There is pressure to sell the vaccine at a "fair" price.
Meanwhile a lot of other pharma companies are developing their vaccines, so while they are first to announce, they may not be first to market, if they were they would only be able to supply in relatively small amounts (compared to demand) in the first months and a broad spectrum of vaccines is preferable than 1.
Meanwhile the general populace of the western world is not going to doctors as much (less presciptions), not have surgery as much (less meds) due to Covid.
So that's why their share price is where it is.
Thalidomide is a bad example as it is (and always was) safe.
What wasn't safe was the production method that produced something else and not what was researched, that kind of error doesn't happen any more and hasn't for decades.
To those saying vaccines aren't the answer, well, your wrong.
That doesn't mean that testing will go away anytime soon.
So today I learned that a government agency (MHRA) is funded by the government.
And in a a time of global emergency, one of the biggest advocates of science and healthcare donates money to a body that regulates science and healthcare.
Clear evidence of a huge conspiracy that Bill Gates wants us to be injected with microchips.
Information on the AUT (Authorisation for Use) program.
https://www.simon-kucher.com/en-gb/node/5099
What is the ATU program?
ATU status is granted by the French National Agency for Medicines and Health Products Safety (ANSM) to promote fast access to innovation, before marketing authorization and conventional pricing and market access process completion. In order for a drug to be granted ATU status, three key criteria must be met:
The drug must be intended for a serious or rare indication
There must be no other appropriate therapies available for this indication in France
The drug must have presumed efficacy and safety in light of the available scientific data, and the treatment cannot be delayed for patients
Within this program, two types of ATU can be granted. A nominative ATU (nATU) is for one specific identified patient at the request of his or her physician. A cohort ATU (cATU) is designated for a group of patients at the request of the drug manufacturer (with requirements and eligibility criteria differing slightly between the two). ATUs allow early access for thousands of patients each year; roughly 22,000 patients benefited from the ATU program in 2018 alone including over 230 different drugs (2018 ANSM annual report – nATUs: 217 drugs and 15,987 patients; cATUs: 20 drugs and 5,642 patients) which underscores just how extensive the program is. The ATU program was initially designed to guarantee early access mainly to new HIV therapies, but now mostly covers oncology and hematology products as well (see Figure 1).
My understanding was the French info about usage from October 15th came from a screenshot on twitter of the French Doctor.
https://twitter.com/maryau_mcu_ph?lang=en
However, if you check his Twitter posts and replys you can't find the post (well I can't), so either he deleted it, or it was faked.
Launching onto the French market would be momentous news and worthy of an RNS weeks ago on our side and fanfare in France, which is why I'm more than a little skeptical.
Happy to be proved wrong tho.
To be fair we've also heard from about a hundred different experts on this board about the timing of SNG and they are 99.9% wrong.
It would appear that the experts are really just speculating about stuff they don't fully know about. But then most of them have a microphone shoved in front of their mouths and are asked questions. which they answer to the best of their abilities..
It is all speculation.
Well, yesterday we had a share price of about £2 and were looking forward to a peer reviewed release of COVID data or regulatory/partnership news.
And today we had a share price of about £2 and were looking forward to a peer reviewed release of COVID data or regulatory/partnership news.
We've had a COPD RNS which was overall good and a RM interview which was better, but if you believed in SNG already, nothing much has changed.
p<=0.001.
You can see it on the Synairgen website..
"Over the treatment period, lung antiviral responses to viral infection were significantly
enhanced in patients receiving SNG001 compared to those on placebo, as assessed
by measuring increases in the gene expression of interferon beta-dependent antiviral
biomarkers MX1 (p=<0.001) and OAS1 (p=<0.001) in lung (sputum) cells. Analysis of
blood biomarkers is ongoing."
From the RNS
"On the 20th July 2020 Synairgen announced positive topline data generated from the
101 hospitalized patients in the SG016 trial. The key findings were that the odds of
developing severe disease were reduced by 79% in patients receiving SNG001
compared to placebo, that patients who received SNG001 were more than twice as
likely to recover from COVID-19 as those on placebo, and that their breathlessness
was markedly reduced. Further analysis of the full data set is being conducted, with a
peer-reviewed publication expected in due course."
So.. In Due Course.
No, it's antiviral, so unless you've got a virus you won't want to take it.
If it's because it increases Peak Flow Rate in the lungs, the people who are being tested have a depressed Flow Rate, so it's about restoring Flow Rate.
Also with regards to legality, blood doping is 100% natural, you are injecting your own blood.
That's 100% illegal in sport.
Didn't know what BCSS was, Dr Google says...
The Breathlessness, Cough and Sputum Scale (BCSS) is a patient-reported outcome measure to evaluate symptoms in patients with chronic obstructive pulmonary disease (COPD). The BCSS is a daily diary that asks patients to rate the severity of the three symptoms, each on a 5-point scale; higher scores indicate more severe symptoms. Item scores are summed to yield a total score.
Developed and used for diary card and eDiary administration
Takes approx 1-2 minutes to complete
Recall period is “today”, to be completed in the evening
Each item is rated on a 5-point Likert scale
Developed for adult patients with a COPD disease
No, it's not linked.
Pretty sure if your a statistician working in Southampton you're primary motivation to get results out is not going to be a person on another continent giving a scheduled talk which is never going to mention anything you are working on.
Now who is going to be first to suggest that Trump monitors SNG and will jump all over this RNS, or that Boris needs to read it out word for word in Parliament while wearing a 3 piece Union Jack Suit?